- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02784314
Cost Efficacy Evaluation of Robot Assisted Radical Prostatectomy (ROBOTCAP)
June 2, 2017 updated by: Hospices Civils de Lyon
Medico-economic Evaluation of Robotic-assisted Radical Prostatectomy Versus Laparoscopic Radical Prostatectomy
In this observational cost efficacy study, the investigator compare the Laparoscopic Radical Prostatectomy (LRP) versus Robotic-Assisted Laparoscopic Prostatectomy (RALP).
Every cost of care that include hospitalization related or post operative medical consumption are obtained and recorded up to 5 years follow up.
Functional results (continence, potency, quality of life) are obtained through standardised questionnaires.
Carcinologic results are estimated by Prostate Specific Antigen (PSA) relapse and salvage treatments.
Economic evaluation will be made to estimate direct costs of the four postoperative year along with the incremental cost-effectiveness ratio (ICER) per successful surgical treatment (preserved urinary continence and erectile function and PSA < 0.2).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bordeaux, France, 33074
- Service d'Urologie - Clinique St Augustin
-
Lyon cedex 03, France, 69437
- Service d'Urologie et Chirurgie de la Transplantation - Hôpital Edouard Herriot -Hospices Civils de Lyon
-
Paris, France, 75014
- Service d'Urologie - Institut Mutualiste Montsouris
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Localized prostate cancer
- Gleason grade ≤ 3 + 4
- PSA < 15 ng / mL
- Stage ≤ T2b
- Eligible to receive laparoscopic radical prostatectomy
- Candidate bilateral or unilateral erectile preservation
Exclusion Criteria:
- Patient at high risk of postoperative progression (PSA> 15 ng / mL; grade 5 predominant, clinical or radiological stage T3
- Presenting erectile dysfunction (IIEF < 22)
- Past history of urinary incontinence (> grade 1 WHO)
- Body mass index > 30
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Robotic-Assisted Radical Prostatectomy
Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System
|
|
Active Comparator: Laparoscopic Radical Prostatectomy
Standard laparoscopic Radical Prostatectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Erectile function
Time Frame: 12 months after surgery
|
Proportion of patients with recovery of erectile function between T0 (before surgery) and 12 months after surgery.
Recovery is defined as a maximum decrease of 5 points score of the International Index of Erectile Function (IIEF) between pre and postoperative evaluations.
|
12 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical margins
Time Frame: During surgery
|
During surgery
|
|
Prostate Specific Antigen (PSA)
Time Frame: Before surgery (T0), 6 months (M6), 12 months (M12), 24 months (M24) and 60 months (M60) after surgery
|
Before surgery (T0), 6 months (M6), 12 months (M12), 24 months (M24) and 60 months (M60) after surgery
|
|
Continence
Time Frame: Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12), 24 months (M24) and 60 months (M60) after surgery
|
Continence is assessed by the International Prostate Symptom Score (IPSS)
|
Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12), 24 months (M24) and 60 months (M60) after surgery
|
Tolerance
Time Frame: Perioperative period, 6 months (M6), 12 months (M12) and 24 months (M24) afer surgery
|
Adverse events related to the perioperative prostatectomy, 6 months, 12 months and 24 months afer surgery
|
Perioperative period, 6 months (M6), 12 months (M12) and 24 months (M24) afer surgery
|
Quality of life
Time Frame: Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12) and 24 months (M24) after surgery
|
Quality of life is assessed by EQ-5D, QLQ-C30 and QLQ-PR25 scores
|
Before surgery (T0), 6 months (M6), 9 months (M9),12 months (M12) and 24 months (M24) after surgery
|
Incremental cost-effectiveness ratio
Time Frame: 60 months afet surgery
|
Economic evaluation will be made to estimate direct costs of the five postoperative years along with the incremental cost-effectiveness ratio (ICER) per successful surgical treatment
|
60 months afet surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
May 1, 2013
Study Completion (Actual)
August 1, 2016
Study Registration Dates
First Submitted
May 20, 2016
First Submitted That Met QC Criteria
May 24, 2016
First Posted (Estimate)
May 27, 2016
Study Record Updates
Last Update Posted (Actual)
June 5, 2017
Last Update Submitted That Met QC Criteria
June 2, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009.587
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on Robotic-Assisted Radical Prostatectomy
-
University of LeipzigHeinrich-Heine University, Duesseldorf; University Hospital Heidelberg; Klinikum...Completed
-
Aesculap AGB.Braun Surgical SARecruiting
-
Ankara City Hospital BilkentRecruitingProstatectomy | Kidney Function Tests | Neutrophil Gelatinase-Associated LipocalinTurkey
-
Shanghai Changzheng HospitalShanghai Zhongshan Hospital; The First Affiliated Hospital of Guangzhou Medical... and other collaboratorsRecruitingProstate Adenocarcinoma | Localized Prostate CarcinomaChina
-
Herlev and Gentofte HospitalCompletedUrinary Incontinence | Erectile Dysfunction | Male Urogenital Diseases | Prostatectomy | HumansDenmark
-
Mayo ClinicTerminatedAdenocarcinoma | Prostatic NeoplasmsUnited States
-
Imperial College LondonImperial College Healthcare NHS Trust; Experimental Cancer Medicine CentresRecruitingObesity | Prostate CancerUnited Kingdom
-
Ankara City Hospital BilkentNot yet recruitingRobotic Surgery | Low Flow Anesthesia | Normal Flow AnesthesiaTurkey
-
Ankara UniversityRecruitingProstate Adenocarcinoma | Urinary Incontinence,Stress | Cancer of Prostate | Erectile Dysfunction Following Radical ProstatectomyTurkey
-
Istituto Auxologico ItalianoUnknownUrinary Incontinence | Prostate CancerItaly